

# Index

- 22q11.2 deletion syndrome, 383, 541
- acceptance and commitment therapies (ACT), 422
- acetylcholine, 18, 20
  - ascending neurotransmitter system, 113–114
  - basic pharmacology, 30
  - key cognitive functions, 115
  - role in delirium, 503
  - role in promoting wakefulness, 135
- acetylcholine receptors, 30
- acetylcholinesterase (AChE), 20
- acetylcholinesterase inhibitors, 249
- acromegaly, 295
- ACTH (adrenocorticotrophic hormone), 36
- action potential, 9–10
- Adderal, 226
- addiction, 36, 92, 359, 403–407
  - craving, 407
  - interactions between drugs of abuse and the meso-corticolimbic system, 404–405
  - neuroadaptations in response to drug use, 403
  - neurocircuitry of, 403–404
  - outstanding questions, 407
  - relapse, 407
  - tolerance, 405–407
  - withdrawal, 405–407
- Addison's disease, 289–290
- adenosine
  - role in sleep regulation, 140
- adrenal insufficiency, 289–290
- adrenal steroids, 307–314
  - changes during an episode of MDD, 312
  - conclusions on effects of cortisol, 314
  - cortisol dysregulation in psychiatric disorders, 314
  - DHEA moderator of cortisol actions, 314
  - effects of cortisol levels on memory, 312
  - effects of early-life adversity on the HPA axis, 308
  - glucocorticoids as a risk factor for MDD, 309–310
  - hormones and psychological symptoms, 307–308
  - individual differences in glucocorticoid function, 308–309
  - outstanding questions, 314
  - possible causal mechanisms in MDD, 310–312
  - therapeutics of MDD and glucocorticoids, 313–314
- adrenaline, 18, 19
- Adult Attachment Interview (AAI), 355
- aggression. *See* violence and aggression
- agomelatine, 520
- agonistic spectrum of chemicals, 24–25
- AGRP (agouti related peptide), 37
- Ainsworth, Mary, 354–355
- akathisia, 181–182
- alcohol and substance use disorder, 161
- alcohol use, 32
  - association with violence, 167
  - cognitive decline and, 571
  - effects on neurotransmission, 49
  - movement disorders caused by, 178
  - overview of effects, 45
  - tolerance and withdrawal, 406
- alcohol withdrawal delirium (AWD), 503–504
- alexia, 273, 274–275
- allocortex, 84
- allopregnanolone (ALLO), 152–153, 154, 155
- Alzheimer's disease, 112, 152, 233
  - alterations in brain structure, function and organisation, 350
  - attentional deficits, 229
  - cholinergic hypothesis of, 113
  - decrease in grey matter volume, 345
  - language dysfunctions, 275–276
  - See also* dementia; neurodegeneration.
- amino acid neurotransmitters, 18
- amisulpride, 155
- amitriptyline, 27, 493, 520
- AMPA receptors, 31
- amphetamines, 30, 226, 229, 238
  - effects on neurotransmission, 50
  - overview of effects, 45
- amygdala, 97–100, 102, 108, 111, 113
  - effects of increased corticoid levels, 303
  - reward processing, 203–204
  - role in emotion, 214
  - role in emotional memory, 246
- amyotrophic lateral sclerosis–parkinsonism–dementia complex of Guam, 571
- anhedonia, 92, 233–239
  - blunted reward prediction errors, 187
  - brain mechanisms in amotivation, 237–238
  - cognitive components of motivation, 234–237
  - definition of, 233–234
  - functional neuroimaging studies, 238
  - lesion and stimulation studies, 237–238
  - measurement of, 234
  - outstanding questions, 239
  - prevalence in different conditions, 233
  - role of dopamine, 238
- animal models, 67
  - anomia, 275
  - violence and aggression, 162

## Index

- anorectic (appetite reducing) neuropeptides, 36–37
- anorexia nervosa, 122, 155  
 biological changes in, 530–531  
 diagnostic criteria (DSM-V), 530  
 features of, 529–530
- antidepressant drugs  
 how they work, 442–443
- antidiuretic hormone (ADH), 125, 296
- antipsychotic drugs  
 extrapyramidal side effects, 181–182
- antisocial personality disorder, 161, 162
- anxiety disorders, 29, 125, 410–413  
 animal models, 68  
 anxiety neurocircuitry, 410–411  
 association with immune alterations, 318  
 clinical features, 410  
 fear neurocircuitry, 410–411  
 genetic predispositions to, 412  
 genome-wide association study (GWAS), 330  
 neurotic personality subtype, 412  
 neurotransmitter systems, 411–412  
 outstanding questions, 413  
 pharmacological treatments, 211  
 prevalence across the lifespan, 412  
 psychic (cognitive) and somatic components, 211  
 role of endogenous opioids, 412  
 role of inflammation, 412–413  
 role of neuropeptides, 412  
 sex differences, 152  
 sleep disorders, 520  
 somatic anxiety, 211  
 types of, 410  
*See also* emotional disorders.
- apathetic hyperthyroidism, 292
- apathy, 92, 233–239  
 brain mechanisms in amotivation, 237–238  
 cognitive components of motivation, 234–237  
 definition of, 233–234  
 functional neuroimaging studies, 238  
 lesion and stimulation studies, 237–238  
 measurement of, 234  
 outstanding questions, 239  
 prevalence in different conditions, 233  
 role of dopamine, 238
- aphasias, 273–275  
 primary progressive aphasia (PPA), 275
- appetite  
 drugs that affect appetite and mood, 124–125  
 hedonic food intake, 121  
 homeostatic regulation by the hypothalamus, 121  
 influence of neuropeptides, 36–37  
 influence of peripheral peptides, 124  
 leptin-responsive neural circuits, 123–124  
 neural circuits, 121–126  
 neuroanatomy of, 121  
 outstanding questions, 126  
 regulation of, 36  
 regulatory role of leptin, 121–123  
 relationship to thirst, 125  
 role of ghrelin, 124
- apraxia, 178
- apraxia of speech, 273
- arachnoid mater, 84
- arginine vasopressin (AVP), 34, 38, 296  
 AVP deficiency (cranial diabetes insipidus), 297  
 AVP resistance (nephrogenic diabetes insipidus), 297
- argomelatine, 155
- aripiprazole, 155, 296, 520
- arousal  
 involvement of neuropeptides, 37–38
- astrocytes, 13
- atomoxetine, 30, 229
- atropine, 503
- attachment, 354–363  
 ABC+D model of attachment types, 354–355  
 Adult Attachment Interview (AAI), 355  
 animal models, 357–358  
 behavioural studies, 357  
 Dynamic-Maturation Model of Attachment and Adaptation (DMM), 355–356  
 implications for caregivers, 358–361  
 influence of oxytocin, 358  
 influence on risk of psychiatric conditions, 357  
 maternal attachment, 358–361  
 neurobiology of attachment in humans, 358–361  
 new therapies from neurobiology, 361  
 outstanding questions, 363  
 role of fathers and other caregivers, 359–361  
 Strange Situation Procedure (SSP), 354–355  
 theories of attachment, 354–356  
 work of John Bowlby, 354  
 work of Mary Ainsworth, 354–355  
 work of Mary Main, 355  
 work of Patricia Crittenden, 355–356
- attention, 225–230  
 bottom-up (exogenous) attention, 225  
 definition of, 225  
 forms of, 225  
 influence of motivation and arousal, 225  
 measurement of, 226  
 neural basis of, 226–227  
 outstanding questions, 230  
 pre-pulse inhibition, 225, 229  
 role of the prefrontal cortex, 258  
 selective attention, 225  
 sustained attention, 225  
 top-down (endogenous) attention, 225  
 vigilance, 225

- attention deficit/hyperactivity disorder (ADHD),  
30, 110, 397–400  
aetiology, 397–398  
association with immune alterations, 318  
brain connectivity alterations, 398  
brain mechanisms, 398  
definition of, 397  
dopamine hypothesis of ADHD, 398  
executive function deficit, 253  
features of, 397  
functional imaging, 228  
heritability, 327, 397–398  
mechanisms of attentional deficits, 227–228  
neurotransmitter alterations, 398  
neurotransmitter genes implicated by GWAS, 43  
outstanding questions, 400  
pharmacological treatments for attention deficits,  
229  
prototypical syndrome of attentional impairment,  
225–226  
rate of rare copy number variants, 333  
structural brain alterations, 398  
structural imaging, 227–228
- attention networks, 255
- attentional deficits  
ADHD as prototypical syndrome, 225–226  
functional imaging in ADHD, 228  
in psychiatric disorders other than ADHD, 229–230  
mechanisms in ADHD, 227–228  
pharmacological treatments in ADHD, 229  
structural imaging in ADHD, 227–228
- auditory system, 220
- autism spectrum disorder (ASD), 389–394  
application of learning models, 189  
Asperger's syndrome, 393  
association with immune alterations, 318  
behavioural definition of, 389–390  
features of, 389  
heritability, 327  
heterogeneous neurodevelopmental condition,  
389–390  
molecular–neurobiological bases, 392–393  
neurocognitive bases, 390–392  
neurotransmitter genes implicated by GWAS, 43  
outstanding questions, 394  
patterns of atypical development, 349–350  
rate of rare copy number variants, 333  
social cognition issues, 261  
Theory of Mind deficits, 265
- autonomic nervous system, 81, 82
- autoradiography, 57
- back pain, 173
- baclofen, 30
- barbiturates, 29
- Bard, Philip, 209–211
- Barlow, Horace, 222
- basal ganglia, 90–92, 111
- Bayesian learning models, 187–189
- Bayesian statistical approaches, 69
- Beers Criteria for Potentially Inappropriate Medication Use in  
Older Adults, 504
- Behavioural Activation therapy, 235
- behavioural inflexibility, 112
- benzodiazepines, 29–30, 67, 211, 368, 411  
delirium and, 503–504  
effects on neurotransmission, 48–49  
overview of effects, 45
- Berger, Hans, 129, 538
- beta-blockers, 166, 211
- Binet, Alfred, 378
- binge eating disorder, 532  
biological alterations in, 533
- Bini, Lucio, 544
- biopsychosocial model of health and illness, 491–493
- bipolar affective disorder, 155, 156, 449–454  
association with immune alterations, 318  
characteristics of, 449  
executive function deficit, 253  
genetic factors, 449  
genome-wide association study (GWAS), 330  
heritability, 327  
insights from neuroimaging, 451–453  
neurotransmitter genes implicated by GWAS, 41, 42  
outstanding questions, 454  
peripheral biological markers, 453–454  
rate of rare copy number variants, 333  
role of neurotransmitters, 449–450  
role of signal transduction systems, 450  
sleep disorders, 520  
thyroid hormone therapy in depression, 292–293
- Bliss, Tim, 243
- block designs, 71
- blood–brain barrier, 13, 86, 303, 317
- blunted reward prediction errors, 187
- Bodily Distress Syndrome (ICD-11), 490
- body dysmorphic disorder  
definition of, 429  
*See also* obsessive–compulsive and related disorders  
(OCDs).
- Bonnet, Charles, 222–223
- borderline personality disorder, 161, 215, 261, 477–481  
brain structure, 479  
diagnostic criteria, 477  
features of, 477  
functional neuroimaging, 479  
genetic factors, 480  
neuroendocrinology of, 478–479  
neuroscientific approaches, 477–478  
outstanding questions, 481  
vulnerability factors, 480
- Bowlby, John, 354
- brain  
grey and white matter, 10  
interactions with the immune system, 317  
neuroanatomy, 79–81

## Index

- brain cells
  - astrocytes, 13
  - glial cells (glia), 13
  - microglia, 13
  - oligodendrocytes, 13
  - Schwann cells, 13
  - See also* neurons.
- brain-derived neurotrophic factor (BDNF), 124
- brain development. *See* neurodevelopment
- brain function
  - autoradiography, 57
  - chemogenetics, 65
  - computerised tomography (CT), 60–61
  - cyclic voltammetry, 57
  - electroconvulsive therapy (ECT), 65
  - electroencephalography (EEG), 57–59
  - immunocytochemistry, 57
  - intracellular electrode recording, 55
  - lesion studies, 65
  - local chemical measurement, 57
  - local field potentials (LFPs), 55
  - magnetic resonance imaging (MRI), 62–64
  - magnetoencephalography (MEG), 59–60
  - microdialysis, 57
  - optical single-cell imaging, 56
  - optogenetics, 65
  - patch clamp technique, 56
  - perturbing brain function, 65–66
  - positron emission tomography (PET), 61–62
  - post-mortem tissue analysis, 57
  - recording from the surface, 57–60
  - recording techniques, 55–64
  - repetitive transcranial magnetic stimulation (rTMS), 65
  - single-photon emission computed tomography (SPECT), 62
  - single-unit electrophysiology, 55–56
  - small-scale recording techniques, 55–56
  - three-dimensional neuroimaging techniques, 60–64
  - transcranial direct current stimulation (tDCS), 65
  - vagus nerve stimulation (VNS), 66
- brain networks, 279–284
  - abnormalities in schizophrenia, 280
  - conceptions of brain networks at different levels, 279
  - connectome (brain graph), 279
  - degree (topological measure), 279
  - dysconnectivity and mental health disorders, 280
  - human MRI brain network mapping, 280
  - modules, 279
  - outstanding questions, 284
  - rich club organisation, 279
  - small-worldness, 279
  - topology, 279
- brain plasticity. *See* neuroplasticity
- brain stimulation, 549–551
  - challenges for future research, 551
  - deep brain stimulation (DBS), 550–551
  - inter-individual variability, 551
  - mechanistic approaches, 551
  - non-invasive brain stimulation, 549–550
  - outstanding questions, 551
  - placebo control, 551
  - role in treating psychiatric disorders, 549
  - targeting deeper structures, 550–551
  - transcranial direct current stimulation (tDCS), 549–550
  - transcranial magnetic stimulation (TMS), 549–550
- brainstem, 79
- brexanolone, 154
- brief eclectic psychotherapy for PTSD (BEPP), 422
- Broca, Paul, 108
- Broca's aphasia, 273, 275
- Brodman areas, 84
- bromocriptine, 28
- Brunner syndrome, 165
- bulimia nervosa, 156, 531–532
  - biological alterations in, 533
- bupropion, 125, 155, 238, 520
- bupirone, 520
- cabergoline, 296
- caffeine, 67, 140
- cancer-therapy related cognitive impairment ("chemo fog"), 320
- cannabis
  - effect on appetite, 125
  - effects on neurotransmission, 49
  - overview of effects, 45
- Cannon, Walter, 209–211
- carbamazepine, 32, 178
- cataplexy, 37, 518
- catatonia, 181, 473
- causation
  - correlation and, 69
- cells, 5
- central executive network, 506
- central nervous system (CNS), 77
  - neuroanatomy, 79–81
- cerebellum, 81
- cerebral cortex, 79–80, 84–85
  - regions associated with memory, 246–247
  - role in regulation of emotion, 214
- cerebral peduncles, 81
- cerebrospinal fluid (CSF), 88
- Cerletti, Ugo, 544
- chemical synapses, 17–20
  - classification of neurotransmitter receptors, 22–23
  - features of, 17
  - ion channels and calcium flux, 18
  - ionotropic receptors, 17, 22–23
  - metabotropic receptors, 17, 22–23
  - neurotransmitter storage, release and reuptake, 20
  - neurotransmitter synthesis, 18
  - synapse physiology, 18
  - synaptic cleft, 18
- chemogenetics, 65
- child abuse, 167
- childbirth. *See* perinatal disorders

- childhood adversity  
 biological resilience factors, 371  
 borderline personality disorder risk factor, 480  
 impact of parental postnatal depression, 370  
 impact of poverty on neurodevelopment, 368  
 impact on neurodevelopment, 368–371  
 influence on the HPA axis, 308  
 neural effects of uncontrolled stress, 369–370  
 neuroanatomical changes, 492  
 social resilience factors, 370
- chlorpromazine, 166, 503
- cholecystokinin (CCK), 124
- cholinesterase inhibitors, 30, 113
- chronic pain syndromes, 320
- circadian process  
 role in sleep regulation, 130–132
- circadian rhythm, 81, 140–141  
 molecular regulation of the circadian clock, 140–141  
 suprachiasmatic nucleus inputs, 140  
 suprachiasmatic nucleus outputs, 140  
 synchronisation and maintenance, 140
- circadian rhythm sleep–wake disorders, 518
- citalopram, 27
- clomipramine, 520
- clonidine, 30, 423
- clozapine, 27, 28, 125, 155, 166, 181, 471, 503, 520
- cocaine, 181  
 effects on neurotransmission, 49  
 overview of effects, 45
- cognition  
 influence on emotion generation and regulation, 214
- cognitive and behavioural therapies  
 strategies to treat anxiety and mood disorders, 215
- cognitive behavioural therapy (CBT), 422
- cognitive control  
 role of the prefrontal cortex, 259–260
- cognitive flexibility  
 aspect of executive function, 255  
 role of the prefrontal cortex, 258–259
- complex regional pain syndrome (CRPS), 490–491
- compulsive behaviours  
 application of learning models, 185–187  
 role of habits and goals, 195–196
- computational modelling of behaviour, 70
- computational models, 84  
 linking brain function to behaviour, 184  
 prediction error-driven learning, 184
- computational models of learning. *See* learning models
- computational neuroscience, 12
- computerised tomography (CT), 60–61
- conduct disorder, 161, 314
- confounding factors, 69, 70
- confusional arousal, 518
- construct validity, 67
- corpus callosum, 106–107
- cortex. *See* cerebral cortex
- corticobasal degeneration, 557, 559, 560
- cortisol, 36  
 changes during an episode of MDD, 312  
 conclusions on association with mental symptoms, 314  
 dysregulation in psychiatric disorders, 314  
 effects on memory, 312  
 individual differences in levels and daily rhythms, 308–309  
 moderating effect of DHEA, 314  
 outstanding questions, 314  
 release in response to stress, 301–302
- cranial diabetes insipidus (AVP deficiency), 297
- cranial nerves, 82–83
- Creutzfeldt–Jakob disease, 560
- Crittenden, Patricia, 355–356
- Cushing’s disease, 303, 309
- Cushing’s syndrome, 290–291
- cyclic voltammetry, 57
- D-cycloserine, 423
- cytoarchitectonics, 84
- data analysis, 69–70
- decision making  
 role of the prefrontal cortex, 260
- deep brain stimulation (DBS), 65, 550–551
- default mode network (DMN), 71, 227, 255, 392, 400, 469, 506
- delirium, 497–506  
 acute precipitants, 498  
 alcohol withdrawal delirium (AWD), 503–504  
 arousal and, 504  
 benzodiazepines and, 503–504  
 brain energy metabolism dysfunction, 505  
 characteristics of, 497  
 circadian rhythms and, 504  
 clinical description, 498  
 clinical management, 498–500  
 concept of, 497–498  
 delirium disorder model, 498  
 excitatory–inhibitory imbalance, 503–504  
 impaired network function and, 505–506  
 inflammation and, 505  
 outstanding questions, 506  
 relationship to dementia, 500  
 role of acetylcholine, 503  
 role of dopamine and antipsychotics, 503  
 role of glutamate and GABA, 503–504  
 sleep–wake cycles and, 504  
 specific neurophysiological accounts, 503–504  
 systemic physiological accounts, 504–506  
 underlying pathophysiology, 503–506  
 vulnerability for, 498
- delusions, 456–457, 459–460
- dementia, 30, 32, 246  
 alterations in brain structure, function and organisation, 350  
 attentional deficits, 229  
 forms of memory impairment, 247–248  
 language dysfunctions, 275–276  
 memory disorders, 247–249  
 relationship to delirium, 500  
 treatments for memory disorders, 249  
*See also* neurodegeneration.

## Index

- depressant recreational drugs, 45–49  
 depression, 66, 110, 111, 112, 122, 154  
   animal models, 68  
   association with immune alterations, 318  
   effectiveness of ECT, 544  
   executive function deficit, 253  
   in epilepsy, 540  
   liking (subjective enjoyment), 235  
   neurotransmitter genes implicated by GWAS, 41, 42–43  
   pharmacological treatments, 211  
   psychic (cognitive) and somatic components, 211  
   sleep disorders, 520  
   social cognition issues, 261  
   *See also* emotional disorders; major depressive disorder (MDD).  
 desipramine, 520  
 dexamethasone, 303  
 dexamethasone suppression test (DST), 312  
 dexmedetomidine, 504  
 DHEA (dehydroepiandrosterone), 154, 155  
   moderator of cortisol actions, 314  
 diabetes, 572  
   sleep deprivation and, 142  
   type 2, 125  
 diazepam, 29, 32, 48  
   effectiveness in anxiety disorders, 211  
 DiGeorge syndrome, 383, 541  
 diphenhydramine, 503  
 dissociative/conversion disorders (ICD-10/11; DSM-5), 490  
 DMT (N,N-dimethyltryptamine)  
   overview of effects, 45  
 donepezil, 249  
 L-DOPA, 238  
 dopamine, 18, 19  
   ascending neurotransmitter system, 112–113  
   basic pharmacology, 28  
   effects of dopamine dysfunction, 28  
   effects on sleep and arousal, 135  
   key cognitive functions, 115  
   role in delirium, 503  
   role in motivation, 238  
   role in pleasure and euphoria, 204  
   role in reward and learning, 112–113  
   role in violence and aggression, 166  
 dopamine hypothesis of ADHD, 398  
 dopamine neurons  
   reward signal, 202  
 dopamine receptors, 28  
 dopamine transporter (DAT), 20, 28, 62  
 dorsal striatum, 90  
 Down syndrome, 333, 383  
 doxepin, 520  
 drug induced parkinsonism, 182  
 drug targets, 24–25  
   neuropeptide receptors, 38  
 drug use, 403–407  
   alcohol tolerance and withdrawal, 406  
   craving, 407  
   initial use and the meso-corticolimbic reward system, 403–404  
   interactions between drugs of abuse and the meso-corticolimbic system, 404–405  
   neuroadaptations in response to, 403  
   neurocircuitry of addiction, 403–404  
   opiate tolerance and withdrawal, 406–407  
   outstanding questions, 407  
   relapse, 407  
   tolerance, 405–407  
   withdrawal, 405–407  
 drugs  
   effects on appetite and mood, 124–125  
 duloxetine, 493, 523  
 dura mater, 84  
 dynorphins, 34–36  
 dysarthria, 273  
 dysgraphias, 273–275  
 dyskinesias, 181, 472–473  
 dyslexias, 273–275  
 eating disorders, 155, 529–533  
   anorexia nervosa, 529–531  
   binge eating disorder, 531–533  
   bulimia nervosa, 531–533  
   features of, 529  
   outstanding questions, 533  
   role of leptin, 121–123  
 ecstasy (MDMA)  
   effects on neurotransmission, 50  
   overview of effects, 45  
   use in PTSD, 423  
 electroconvulsive therapy (ECT), 59, 65, 544–546  
   cognitive side effects, 545–546  
   effectiveness of, 544  
   mechanism of action, 544–545  
   outstanding questions, 546  
 electroencephalography (EEG), 57–59, 538  
 embryology of the nervous system, 78–79  
 emotion, 208–216  
   basic and more complex emotions, 208  
   Cannon–Bard model, 209–211  
   clinical importance of emotion and its regulation, 209  
   cortical regulation of emotion, 214–215  
   defining emotions and emotional behaviour, 208–209  
   dysregulation in many brain disorders, 209  
   galvanic skin resistance (GSR), 209  
   influence of cognition on emotion generation and regulation, 214–215  
   James–Lange theory, 209  
   measures of emotional responses, 208–209  
   neuroanatomy of, 214–215  
   physiological responses associated with, 209–211  
   positive or negative reinforcers, 208  
   role of the amygdala, 214  
   role of the limbic system, 214  
   Schachter and Singer hypothesis, 211



- skin conductance response, 209
- subcortical structures, 214
- theories of, 209–211
- Emotion Recognition from the Eyes Test, 268
- emotional disorders
  - aetiology of, 211–212
  - developmental vulnerabilities, 211–212
  - neurobiological insights from fMRI, 215
  - outstanding questions, 216
  - pharmacological treatments and emotion theories, 211
  - psychic (cognitive) and somatic components, 211
  - treatment development challenges, 216
- emotional memory
  - role of the amygdala, 246
- emotionally unstable personality disorder. *See* borderline personality disorder
- empathy, 260, 261
  - Theory of Mind, 263–268
- endocannabinoids, 37
- endocrine responses to stress, 301–302
- endogenous opioids, 35–36
  - role in anxiety disorders, 412
- endorphins, 34–36
- enhanced learning from punishments, 187
- enkephalins, 36
- enteric nervous system, 124
- epigenetics
  - effects in psychiatric disorders, 336
  - definition of a seizure, 536
  - definition of epilepsy, 536
  - EEG investigations, 538
  - epileptogenesis, 536–537
  - genetic factors, 539–540
  - investigations, 538–540
  - mechanisms that create seizures, 537–538
  - neuroimaging, 538–539
  - neuropsychiatric comorbidity, 540
  - outstanding questions, 541
  - post-ictal psychosis, 540
  - seizure monitoring, 59
  - seizure types, 536
  - vagus nerve stimulation (VNS), 66
- esketamine, 50
- ethanol. *See* alcohol use
- event-related designs, 71
- evolutionary perspective
  - intelligence, 380
- excitatory amino acid transporter (EAAT), 31
- excoriation disorder
  - definition of, 377
  - See also* obsessive–compulsive and related disorders (OCRDs).
- executive dysfunction
  - association with frontal lobe disorders, 253–255
  - disorders associated with, 253
- executive function, 253–261
  - attention, 258
  - cognitive control, 259–260
  - cognitive flexibility, 255, 258–259
  - decision making, 260
  - definition of, 253
  - inhibitory control, 259–260
  - measurement of, 255
  - outstanding questions, 261
  - processes involving the prefrontal cortex, 255–261
  - relationship to intelligence (IQ), 255
  - response inhibition, 255
  - social and ‘hot’ cognition, 260–261
  - three major building blocks of, 255
  - translating neuroscience to new treatments, 261
  - updating working memory, 255
  - working memory, 256–257
- executive network, 227, 255
- exercise
  - impact on stress-induced neuroplasticity, 371
  - therapeutic potential in psychiatric disorders, 371
- expected uncertainty, 113–114
- extrapyramidal side effects of antipsychotic drugs, 181–182
- eye movement desensitisation and reprocessing (EMDR), 422
- face validity, 67
- fatigue, 233–239
  - brain mechanisms in amotivation, 237–238
  - cognitive components of motivation, 234–237
  - definition of, 233–234
  - functional neuroimaging studies, 238
  - lesion and stimulation studies, 237–238
  - measurement of, 234
  - outstanding questions, 239
  - role of dopamine, 238
- Faux Pas Test, 268
- fentanyl, 45
- fibromyalgia, 173, 320, 490
- filum terminale, 84
- fluoxetine, 27, 124, 313, 520
- forebrain, 79–81
- fragile X syndrome, 383
- frontal lobes, 102–103
- fronto-executive functions. *See* executive function
- frontotemporal dementia, 123, 179, 233, 253
  - See also* neurodegeneration.
- frontotemporal lobar degeneration, 567, 572
- functional MRI (fMRI), 64, 71
- functional neuroimaging and connectivity, 71
- functional neurological disorder (FND), 492
- G protein-coupled receptors (GPCRs), 34, 35
  - targeting for therapy, 38
- GABA (gamma-aminobutyric acid), 10, 11, 18, 20
  - basic pharmacology, 29–30
  - role in delirium, 503–504
- GABA (gamma-aminobutyric acid) receptors, 11, 29–30
- gabapentin, 32, 503, 520
- Gage, Phineas, 253
- galantamine, 249
- Galton, Francis, 241
- gastric inhibitory polypeptide (GIP), 124

## Index

- GBL (gamma-butyrolactone)  
   effects on neurotransmission, 49  
   overview of effects, 45  
 gender affirming hormonal therapy (GAHT), 157  
 gender and sex, 147  
 gender identity, 157  
 generalised linear modelling, 69  
 genetic counselling, 337  
 genetics  
   adoption studies, 327  
   basic principles, 327  
   clinical application in psychiatry, 337  
   common variations across psychiatric disorders, 329–332  
   contribution to phenotypic overlaps in psychiatric disorders, 331–332  
   copy number variants associated with psychiatric conditions, 333–334  
   DNA structural variations, 333–334  
   emergence of molecular psychiatric genetics, 327  
   epigenetic effects in psychiatric disorders, 336  
   family-based studies, 327  
   genome-wide association studies (GWAS), 329–331  
   GWAS and post-GWAS analysis of schizophrenia, 330–331  
   heritability of psychiatric disorders, 328  
   history of gene identification, 327  
   insights into neurodevelopment, 351  
   outstanding questions, 337  
   polygenic risk scoring, 331  
   psychiatric genetic epidemiology, 327  
   rare single nucleotide variants associated with psychiatric disorders, 334–335  
   rare variations associated with psychiatric disorders, 333–335  
   twin studies, 327  
 genome-wide association studies (GWAS)  
   anxiety and stress-related disorder, 330  
   bipolar affective disorder, 330  
   major depressive disorder meta-analysis, 329–330  
   neurotransmitter genes implicated in ADHD, 43  
   neurotransmitter genes implicated in ASD, 43  
   neurotransmitter genes implicated in bipolar disorder, 42  
   neurotransmitter genes implicated in depression, 42–43  
   neurotransmitter genes implicated in disorders, 41  
   neurotransmitter genes implicated in schizophrenia, 41–42  
   outstanding questions, 43  
   schizophrenia as exemplar, 330–331  
   single nucleotide polymorphisms (SNPs), 41  
 GHB (gamma-hydroxybutyrate), 520  
   effects on neurotransmission, 49  
   overview of effects, 45  
 ghrelin, 37, 124  
 glial cells (glia), 13  
   effects of raised corticoids, 303  
 gliomas, 13  
 globus pallidus, 90  
 glucagon-like peptide 1 (GLP-1), 124  
 glucagon-like peptide 1 receptor (GLP1 R), 125  
 glucocorticoid receptor (GR), 302–303  
   regulation of activity, 310  
 glucocorticoids  
   changes during an episode of MDD, 312  
   effects of cortisol levels on memory, 312  
   effects of early-life adversity on the HPA axis, 308  
   individual differences in function, 308–309  
   possible causal mechanisms in MDD, 310–312  
   psychological effects of disturbances in, 307–308  
   risk factor for MDD, 309–310  
   therapeutics in MDD, 313–314  
 glutamate, 10, 18, 20  
   basic pharmacology, 31  
   role in delirium, 503–504  
 glutamate excitotoxicity, 31  
 glutamate receptors, 10–11, 31  
 goal-directed processing, 192  
 grey matter, 10, 77, 84–85  
   maturation of, 344–345  
 growth hormone deficiency (GHD), 295  
 guanfacine, 504  
 gut–brain axis, 83, 322  
  
 habenula, 103, 107, 187  
 habit formation, 192–196  
   behavioural experiments, 192–193  
   contemporary issues, 194  
   contingency degradation procedure, 193  
   definition of habits, 192  
   distinction between habitual and goal-directed behaviour, 192–193  
   excessive, 430  
   fundamental importance of, 192  
   goal-directed processing, 192  
   habits and goals in compulsivity, 195–196  
   habits and goals in OCD, 194–195  
   interaction between habits and goals, 194  
   model-based planning, 194  
   model-free (trial and error) learning, 194  
   neuroanatomy of habits and goals, 193  
   outcome devaluation test, 192–193  
   outstanding questions, 196  
   reinforcement learning, 185–187  
   routines and, 192  
   stimuli that can elicit a habitual response, 192  
   theoretical foundations, 192  
   two-step task, 194  
 hallucinations, 222–223, 456–457, 458  
 haloperidol, 27, 155, 503  
 Hamilton Anxiety Scale, 211  
 Hebb, Donald, 243  
 Hebbian mechanism, 11  
 heroin, 45, 407  
 herpes simplex encephalitis, 214  
 hindbrain, 81  
 hippocampus, 97, 100, 103, 107, 108, 111, 113  
   effects of increased corticoid levels, 303  
   memory functions, 245–246  
 histamine  
   role in promoting wakefulness, 135



- hoarding disorder  
definition of, 429  
*See also* obsessive–compulsive and related disorders (OCRDs).
- Hodgkin–Huxley model, 9, 12
- Hollow Mask Illusion, 187–189
- homeostasis  
role of neuropeptides, 34
- 5-HT. *See* serotonin
- Huntington's disease, 178, 233  
animal models, 67, 68  
*See also* neurodegeneration.
- hyoscine, 503
- hypercortisolism, 290–291  
non-tumoral (pseudo-Cushings syndrome), 291
- hyperphagia, 124, 125
- hypertension, 572
- hyperthyroidism, 291–292
- hyperventilation syndrome, 490
- hypoadrenalism, 289–290
- hypochondriasis  
definition of, 429  
*See also* obsessive–compulsive and related disorders (OCRDs).
- hypocortisolism, 289
- hypocretin  
role in sleep regulation, 138–139
- hypogonadism, 294
- hyponatraemia, 296–297
- hypothalamic–pituitary (HP) axis, 287–297  
neuroanatomy, 287  
outstanding questions, 297
- hypothalamic–pituitary–adrenal (HPA) axis  
features of, 287–289  
hypercortisolism (Cushing's syndrome), 290–291  
hypoadrenalism (adrenal insufficiency), 289–290  
influence of early-life adversity, 308  
pseudo-Cushings syndrome (non-tumoral hypercortisolism), 291  
psychological manifestations of dysfunction, 289–291  
response to stress, 301–302  
role in PTSD, 417  
screening tests for HPA dysfunction, 291
- hypothalamic–pituitary–gonadal (HPG) axis, 155  
features of, 293–294  
hypogonadism, 294  
investigating HPG function, 294  
psychological manifestations of dysfunction, 294
- hypothalamic–pituitary–somatotrophic (HPS) axis  
acromegaly, 295  
features of, 294–295  
growth hormone deficiency (GHD), 295  
psychological manifestations of dysfunction, 295
- hypothalamic–pituitary–thyroid (HPT) axis  
apathetic hyperthyroidism, 292  
features of, 291  
hyperthyroidism, 291–292  
hypothyroidism, 292  
psychological manifestations of dysfunction, 291–292
- thyroid hormone therapy in depression, 292–293  
thyrotoxicosis, 291–292
- hypothalamic–prolactin axis, 295–296  
hyperprolactinaemia, 296  
psychological manifestations of dysfunction, 296
- hypothalamus, 80–81, 103, 111  
neuroanatomy, 287  
regulation of pituitary function, 287  
role in appetite regulation, 121
- hypothyroidism, 292
- illusions, 222–223, 457  
visual system, 219–220
- imipramine, 27, 30
- immune system, 316–322  
adaptive system, 316–317  
association between psychiatric disorders and immune alterations, 318–320  
biomarkers of immune dysfunction, 318–320  
causal role of immune abnormalities in psychiatric symptoms, 320–321  
functions and features, 316–317  
inflammasome, 318  
inflammation, 316, 317, 318–320  
innate system, 316  
interactions with the brain, 317  
outstanding questions, 322  
pathways to act on the brain to alter mental states and behaviour, 318  
sources of inflammation seen in psychiatric disorders, 321–322
- immunocytochemistry, 57
- impulsivity, 112
- inflammasome, 318
- inflammation, 316–322  
delirium and, 505  
effects of stress on the immune system, 321  
possible causal role in psychiatric symptoms, 320–321  
potential role in anxiety disorders, 412–413  
role in neurodegeneration, 559  
sources of inflammation seen in psychiatric disorders, 321–322
- infliximab, 320
- informational Theory of Mind, 265
- inhibitory control  
role of the prefrontal cortex, 259–260
- insulin, 124
- intellectual disability  
behaviours and traits associated with, 383  
definition of, 381–382  
rate of rare copy number variants, 333  
syndromes, 383
- intelligence, 377–383  
adaptive behaviour, 377  
aspects of, 377  
defining intellectual disability, 381–382  
definition of, 377  
evolutionary models of intelligence and cognition, 380

## Index

- intelligence (*cont.*)  
 evolutionary perspective, 380  
 features of intellectual disability, 383  
 fluid and crystallised intelligence, 379  
 general intelligence (g-factor), 378  
 invention of the intelligence quotient (IQ), 377–379  
 measures of, 377–379  
 neurobiology of, 380–381  
 outstanding questions, 383  
 relationship between IQ and executive function, 255  
 Wechsler Adult Intelligence Scale (WAIS), 379
- intermittent explosive disorder, 161
- intracranial EEG, 57
- ion channels, 7–9  
 voltage-gated ion channels, 9–10
- ionotropic receptors, 17, 22–23
- irritable bowel syndrome (IBS), 173, 490, 491
- James, William, 209, 241
- kainate receptors, 31
- Kallmann syndrome, 294
- ketamine, 32, 42, 423  
 effects on neurotransmission, 50  
 overview of effects, 45
- Klinefelter syndrome, 294, 333
- Konorski, Jerzy, 222
- kuru, 560, 571
- lamotrigine, 32, 42
- language, 271–276  
 definition and features of, 271  
 history of language in neuroscience, 272–273  
 outstanding questions, 276
- language development, 367
- language impairments  
 aphasias, 273–275  
 dysfunctions in neurodegenerative disease, 275–276  
 dysgraphias, 273–275  
 dyslexias, 273–275  
 history of study in neuroscience, 272–273  
 post-stroke disorders, 273–275  
 primary progressive aphasia (PPA), 275  
 variability of, 273–275
- learning  
 reinforcement learning, 200–201  
 reward prediction, 200–201  
 role of dopamine, 112–113  
 role of serotonin, 112
- learning models  
 application in computational psychiatry, 189  
 applied to compulsivity, 185–187  
 applied to mood disorders, 187  
 applied to schizophrenia, 187–189  
 Bayesian learning models, 187–189  
 blunted reward prediction errors, 187  
 computational models, 184–189  
 enhanced learning from punishments, 187  
 features of computational models, 184  
 hierarchical learning models in neuropsychiatry, 189  
 insights into how the brain is functioning, 184  
 outstanding questions, 189  
 prediction error-driven learning, 184  
 reinforcement learning, 185–187
- lentiform (lenticular) nucleus, 90
- leptin  
 role in appetite regulation, 121–123
- leptin-responsive neural circuits, 123–124
- lesion studies of the brain, 65
- levodopa, 28
- Lewy body dementia, 62, 113, 253, 519  
*See also* neurodegeneration.
- limbic-predominant age-related TDP-43 encephalopathy (LATE), 572–573
- limbic system, 86, 108  
 role in emotion, 214
- lithium, 42, 182, 519, 520
- locus coeruleus, 110–111
- Lømo, Terje, 243
- long COVID, 320
- lorazepam, 48
- LSD (lysergic acid diethylamide), 28  
 effects on neurotransmission, 50–51  
 overview of effects, 45
- Lytico–bodig disease, 571
- Machiavellian intelligence, 263
- machine learning, 70
- MacLean, Paul, 86, 108
- magic mushrooms  
 overview of effects, 45
- magnetic resonance imaging (MRI), 62–64, 538–539  
 contraindication, 64  
 functional MRI (fMRI), 64, 71  
 magnetic resonance spectroscopy (MRS), 64  
 pharmacological MRI (phMRI), 64  
 structural MRI, 62–64
- magnetic resonance spectroscopy (MRS), 64
- magnetoencephalography (MEG), 59–60
- Main, Mary, 355
- major depressive disorder (MDD), 113, 152, 155, 233, 439–445  
 application of learning models, 187  
 association with cortisol levels, 314  
 association with endocrine disturbances, 307–308  
 cognitive perspective, 442–443  
 effects of cortisol levels on memory, 312  
 features of, 439  
 glucocorticoid changes during an episode of MDD, 312  
 glucocorticoids as a risk factor for, 309–310  
 GWAS meta-analysis, 329–330  
 heritability, 327  
 how antidepressant drugs work, 442–443  
 linking individual symptoms to neurobiology, 443–445  
 neuroanatomical perspective, 441–442  
 neurochemical perspective, 439–441  
 neuroendocrine perspective, 441

- neuroimmunological perspective, 441
- outstanding questions, 314, 445
- possible causal mechanisms, 310–312
- therapeutics of glucocorticoids, 313–314
- thyroid hormone therapy in depression, 292–293
- MDMA
  - effects on neurotransmission, 50
  - overview of effects, 45
  - use in PTSD, 423
- medically unexplained symptoms, 490–494
  - avoiding stigma, 494
  - biopsychosocial model of health and illness, 491–493
  - classification challenges, 490–491
  - definitions, 490–491
  - investigations and therapies, 493–494
  - neuroscience and, 491–493
  - outstanding questions, 494
  - potential for iatrogenic harm, 493–494
  - relationships with health and social care systems, 493–494
- medulla, 81
- melanocyte stimulating hormone (MSH), 36
- melatonin, 130
- memantine, 32, 249
- memory, 241–249
  - cognitive and psychological divisions, 241–245
  - consolidation, 243–245
  - cortical regions associated with, 246–247
  - effects of cortisol levels, 312
  - effects of prediction error, 244–245
  - episodic memory, 245
  - explicit long-term memory, 245
  - functions of the amygdala, 245
  - functions of the hippocampus, 245–246
  - Hebbian plasticity, 243
  - implicit long-term memory, 245
  - influence on clinical outcomes, 241
  - long-term memory, 241–242
  - long-term potentiation (LTP) process, 31, 243
  - medial temporal lobe structures, 245
  - neuroanatomical divisions, 245–247
  - outstanding questions, 249
  - reconsolidation, 243–245
  - role of serotonin, 112
  - role of the prefrontal cortex, 256–257
  - semantic memory, 245
  - short-term memory, 241–242
  - short-term memory divisions, 243
  - transition to long-term memory, 243–245
  - updating working memory, 255
  - working memory, 256–257
  - Working Memory model (Baddeley and Hitch), 243
- memory disorders
  - dementia, 247–249
  - PTSD, 249
- Mendelian randomisation, 69
- meninges, 84
- mentalisation
  - testing impairments in, 268
- mescaline
  - effects on neurotransmission, 50–51
  - overview of effects, 45
- mesocortex, 84
- metabotropic receptors, 17, 22–23
- methadone, 45, 407
- methylphenidate, 30, 226, 229, 238, 398
- metoprolol, 166
- metryapone, 313
- microbiome, 322, 392
- microdialysis, 57
- microglia, 13
- midbrain, 81
- mifepristone, 313
- mild cognitive impairment (MCI), 561–562, 572
- mindfulness meditation training
  - intervention for stress-induced neuroplasticity, 371–372
  - therapeutic potential of, 371–372
- mindfulness therapies, 422
- mirtazapine, 28, 125, 155, 520
- modelling single neurons and their combinations in circuits, 12
- modulators
  - adrenal steroids, 307–314
  - hypothalamic–pituitary (neuroendocrine) axis, 287–297
  - inflammation and immune responses, 316–322
  - stress responses, 300–304
- Molaison, Henry ('HM'), 241–242
- monoamine neurotransmitters, 18
- monoamine oxidase (MAO), 20
- monoamine oxidase (MAO) inhibitors, 28, 30, 167
  - effects on appetite and weight, 125
- monoamine transporter, 20
- monoamines
  - role in sleep regulation, 135
- mood
  - drugs that affect appetite and mood, 124–125
- morphine, 38, 45
- motion-assisted multi-modular memory desensitisation and reconsolidation (3MDR), 422
- motivation
  - brain mechanisms, 237–238
  - cognitive components of, 234–237
  - functional neuroimaging studies of amotivation, 238
  - lesion and stimulation studies of amotivation, 237–238
  - mechanisms of amotivation, 234
  - positive motivation and reward choice, 201
  - role of dopamine, 238
  - See also* reward.
- motivational Theory of Mind, 264–265
- motor neuron disease, 179
- motor system, 177–182
  - extrapyramidal side effects of antipsychotic drugs, 181–182
  - features of movement control, 177
  - functional movement disorders, 182
  - hierarchy of motor control, 177–178
  - movement disorders, 177–178

## Index

- motor system (*cont.*)  
 movement disorders and psychiatric conditions, 179–181  
 neuroanatomy, 177  
 outstanding questions, 182  
 things not to miss in the psychiatry clinic, 182
- movement disorders, 92  
 antibody-mediated disorders, 179–180  
 associated with recreational drugs, 180–181  
 drug induced parkinsonism, 182  
 extrapyramidal side effects of antipsychotic drugs, 181–182  
 functional movement disorders, 182  
 Huntington's disease, 178, 179  
 motor neuron disease, 179  
 Parkinson's disease, 178, 179  
 psychiatric conditions and, 179–181  
 psychomotor retardation, 178  
 tardive dyskinesia, 182  
 things not to miss in the psychiatry clinic, 182  
 Tourette syndrome, 180  
 Wilson's disease, 179
- multiple chemical sensitivity, 490  
 multiple sclerosis, 179  
 multiple system atrophy, 519  
 muscarinic receptors, 30  
 myeloarchitectonics, 85
- narcolepsy, 29, 30, 37–38, 139, 518  
 narrative exposure therapy (NET), 422  
 nefazodone, 155  
 negative emotional biases, 187  
 neocortex, 84  
 nephrogenic diabetes insipidus (AVP resistance), 297  
 Nernst equation, 8  
 Nernst potential of ions, 7  
 nerve plexuses, 82  
 neural circuits, 85–86  
 apathy, anhedonia and fatigue, 233–239  
 appetite, 121–126  
 attention, 225–230  
 brain networks and dysconnectivity, 279–284  
 computational models of learning, 184–189  
 emotion, 208–216  
 empathy and Theory of Mind, 263–268  
 fronto-executive functions, 253–261  
 habit formation, 192–196  
 language, 271–276  
 memory, 241–249  
 motor system and movement disorders, 177–182  
 nociception and pain, 171–174  
 perception, 219–223  
 reward, pleasure and motivation, 199–205  
 sex and sex hormones, 146–157, 168  
 sleep, 129–143  
 violence and aggression, 161–168
- neuroanatomy  
 arterial supply, 86–87  
 ascending neurotransmitter systems, 110–115  
 basal ganglia, 90–92  
 blood–brain barrier, 86  
 brain, 79–81  
 brainstem, 79  
 Brodmann areas, 84  
 central nervous system (CNS), 77, 79–81  
 cerebellum, 81  
 cerebral cortex, 79–80, 84–85  
 cerebral peduncles, 81  
 cerebrospinal fluid (CSF), 88  
 circuit-level organisation, 85–86  
 circuits, 77  
 cranial nerves, 82–83  
 cytoarchitectonics, 84  
 definition of, 77  
 describing structures in the brain, 77  
 embryology of the nervous system, 78–79  
 fluid compartments, 86–88  
 forebrain, 79–81  
 frontal lobes, 102–103  
 grey matter, 77, 84, 85  
 hindbrain, 81  
 hypothalamus, 80–81  
 macroscopic organisation, 79–84  
 medulla, 81  
 meningeal layers, 84  
 microscopic organisation, 84–85  
 midbrain, 81  
 myeloarchitectonics, 85  
 networks, 77  
 neural circuits, 85–86  
 organisation of the nervous system, 77  
 peripheral nervous system (PNS), 77, 81–83  
 pons, 81  
 reticular formation, 81  
 spinal cord, 81  
 spinal nerves, 82  
 temporal lobes, 97–100  
 terminology, 77  
 thalamus, 80  
 vagus nerve, 83  
 venous drainage, 87  
 white matter, 77, 84, 85  
 white matter pathways, 105–108
- neurodegeneration, 557, 572  
 cascade of causality, 557–560  
 comorbidity, 572–573  
 decrease in grey matter volume, 345  
 dimensional versus categorical approach, 567  
 dual pathology, 572–573  
 environmental causes, 571  
 functional reserve, resilience and resistance, 569–570  
 genetic factors, 557–559  
 heterogeneity of presentations, 567  
 language impairments, 275–276  
 mild cognitive impairment (MCI), 561–562  
 modifiable risk factors, 571  
 outstanding questions, 573  
 preclinical stages, 563–566

- pre-symptomatic biomarkers, 563–566
- prion-like disease progression, 559–560
- prodromal disease, 561–562
- role of inflammation, 559
- neurodegenerative disorders
  - alterations in brain structure, function and organisation, 350
- neurodevelopment
  - attachment, 354–363
  - brain network topology, 346–347
  - development of brain structure and function, 343–347
  - functional maturation and localisation, 346
  - grey matter maturation, 344–345
  - impact of parental postnatal depression, 370
  - impact of poverty, 368
  - impact of stress on, 368–371
  - intellectual disability, 381–383
  - intelligence, 377–383
  - maturation of brain structure, 343–346
  - neural effects of childhood adversity, 369–370
  - neuroplasticity, 366–372
  - resilience to adversity, 370–371
  - role of sex hormones, 367
  - sensitive periods, 368
  - understanding neurodevelopmental disorders, 343
  - white matter maturation, 345–346
- neurodevelopmental models, 349–352
  - atypical development in psychiatric disorders, 349–350
  - autism spectrum disorder (ASD), 349–350
  - challenge to ground psychiatry in biology, 349
  - insights from genetic and transcriptomic studies, 351
  - modelling development *in vitro*, 351
  - neurodegenerative disorders, 350
  - normative models of development, 351–352
  - outstanding questions, 352
  - schizophrenia, 350
  - translational models for assessing psychopathology, 351–352
- neurofilament light protein (NFL), 563–565
- neuroimaging
  - computerised tomography (CT), 60–61
  - fMRI insights into emotional disorders, 215
  - functional connectivity, 71
  - functional imaging in ADHD, 228
  - functional MRI (fMRI), 71
  - functional neuroimaging studies of amotivation, 238
  - insights into bipolar affective disorder, 451–453
  - magnetic resonance imaging (MRI), 62–64
  - perinatal disorders, 513
  - pleasure in humans, 204
  - positron emission tomography (PET), 61–62
  - single-photon emission computed tomography (SPECT), 62
  - structural imaging in ADHD, 227–228
- neurons, 5
  - action potential, 9–10
  - arrangement of, 5–6
  - computational neuroscience, 12
  - connectivity, 5–6
  - depolarisation of the membrane, 8–9
  - electrical capacitance of the membrane, 9
  - hyperpolarisation of the membrane, 9
  - ion channels, 7–9
  - ionic gradients, 7–9
  - membrane potential, 7–9
  - modelling single neurons and their combinations in circuits, 12
  - myelinated and unmyelinated axons, 10
  - Nernst potential of ions, 7
  - neurotransmitter receptors, 10–11
  - physiology of, 7–11
  - plasticity in neuronal circuits, 10
  - resting potential, 7
  - sodium pump membrane transporter, 7
  - speed of action potential propagation, 9
  - structure of, 5
  - synapses, 10
  - types of, 6
  - voltage-gated ion channels, 9–10
- neuropeptide receptors
  - targeting for therapy, 38
- neuropeptides, 34
  - anorectic (appetite reducing) neuropeptides, 36–37
  - arginine vasopressin (AVP), 38
  - future research, 39
  - influence on appetite, 36–37
  - involvement in sleep and arousal, 37–38
  - neuronal signaling mediated by, 34
  - opioid peptides, 34–36
  - orexigenic (appetite stimulating) neuropeptides, 36–37
  - oxytocin, 38
  - pre-propeptide precursors, 34
  - role in anxiety disorders, 412
  - role in homeostasis, 34
  - role in social functioning, 38
  - synthesis and transport, 34
  - environmental influences, 368
  - exercise intervention for the effects of stress, 371
  - experience-dependent plasticity, 368
  - formation of neural circuits, 366–367
  - impact of stress on neurodevelopment, 368–371
  - interventions to rescue stress-induced neuroplasticity, 371–372
  - language development, 366–367
  - mechanisms across the lifespan, 368
  - mindfulness intervention for stress-induced neuroplasticity, 371–372
  - neural circuit mechanisms of sensitive periods, 368
  - outstanding questions, 372
  - processes in early brain development, 366–367
  - role of sex hormones in neurodevelopment, 367
  - sensitive periods, 368
  - synaptic pruning, 366
- neuropsychiatry
  - application of hierarchical learning models, 189
- Neuroscience Based Nomenclature (NbN3), 27

## Index

- neuroscience techniques  
 recording brain function, 55–64
- neurotic personality subtype, 412
- neurotransmission
- neurotransmitter receptors. *See* receptors
- acetylcholine ascending system, 113–114
- acetylcholine pharmacology, 30
- agonistic spectrum of chemicals, 24–25
- alterations in ADHD, 398
- amino acids, 18
- ascending neurotransmitter systems, 110–115
- dopamine ascending system, 112–113
- dopamine hypothesis of ADHD, 398
- dopamine pharmacology, 28
- effects of alcohol, 49
- effects of amphetamines, 50
- effects of benzodiazepines, 48–49
- effects of cannabis, 49
- effects of cocaine, 49
- effects of ecstasy (MDMA), 50
- effects of GHB and GBL, 49
- effects of ketamine, 50
- effects of opioids, 45–48
- effects of psychedelic drugs, 50–51
- function at synapses, 10
- GABA pharmacology, 29–30
- genes implicated in ADHD, 43
- genes implicated in ASD, 43
- genes implicated in bipolar disorder, 42
- genes implicated in depression, 42–43
- genes implicated in schizophrenia, 41–42
- glutamate pharmacology, 31
- GWAS of genes implicated in disorders, 41
- monoamines, 18
- noradrenaline ascending system, 110–111
- noradrenaline pharmacology, 30
- pharmacology of neurotransmitter pathways, 27–31
- role in anxiety disorders, 411
- role in bipolar affective disorder, 449–450
- role in schizophrenia, 469–471
- role in violence and aggression, 164–167
- serotonin ascending system, 111–112
- serotonin pharmacology, 27–28
- small-molecule neurotransmitters, 18
- storage, release and re-uptake, 20
- synthesis of, 18
- trace amines, 19
- transporters, 20
- nicotinic receptors, 30
- nigro-striatal pathway, 112
- NMDA receptors, 11, 31
- nociception and pain, 171–174  
 challenges of pain management, 171  
 chronic pain disorders, 173–174  
 definition of nociception, 171  
 definition of pain, 171  
 functional neuroanatomy of pain, 171–172  
 neuropathic pain, 173
- nociceptive pain, 172–173
- nociplastic pain, 173
- outstanding questions, 174
- pain and disease, 172–173
- pain management in psychiatric disorders, 173–174
- pain pathways, 171–172
- psychiatric diagnoses and chronic pain, 173–174
- stimulus detection and signal transduction by nociceptors, 171
- nodes of Ranvier, 10
- non-cardiac chest pain, 490
- non-verbal therapies, 422
- noradrenaline, 18, 19  
 ascending neurotransmitter system, 110–111  
 basic pharmacology, 30  
 key cognitive functions, 115  
 role in promoting wakefulness, 135  
 role in violence and aggression, 166–167
- noradrenaline and dopamine reuptake inhibitors (NDRIs), 155
- noradrenaline receptors, 30
- noradrenaline reuptake inhibitors (NRIs), 30
- noradrenaline transporter (NET), 20, 30
- noradrenaline
- nortriptyline, 520
- null hypothesis, 69
- obesity  
 drugs that affect appetite and weight, 124–125  
 genetic causes of, 123  
 role of leptin, 121–123  
 sleep deprivation and, 142  
 treatment for, 125
- obsessive–compulsive and related disorders (OCRDs), 429  
 cognitive mediators, 429–431  
 excessive habit formation, 430  
 ICD-11 and DSM-5 definitions, 429  
 impaired cognitive flexibility, 429  
 impaired fear extinction, 430–431  
 impaired inhibition, 429  
 impaired safety signalling, 430–431  
 neural mechanisms, 431  
 neurobiological basis of current treatments, 431–436  
 neuromodulation, 434–436  
 neurosurgery, 433–434  
 outstanding questions, 436  
 pharmacotherapy, 432–433
- obsessive–compulsive disorder (OCD), 65, 92, 550  
 association with immune alterations, 318  
 definition of, 429  
 executive function deficit, 253  
 role of habits and goals, 194–195  
*See also* obsessive–compulsive and related disorders (OCRDs).
- obstructive sleep apnoea (OSA), 518
- olanzapine, 125, 155, 166, 178, 181, 503, 520
- olfactory reference disorder/syndrome  
 definition of, 429  
*See also* obsessive–compulsive and related disorders (OCRDs).



- oligodendrocytes, 13
- ondansetron, 28
- opiates
  - tolerance and withdrawal, 406–407
- opioid peptides, 35–36
- opioids
  - effects on neurotransmission, 45–48
  - exogenous opioids, 45
  - mechanisms of opioid analgesia, 45
  - overview of effects, 45
  - withdrawal, 48
- optical single-cell imaging, 56
- optogenetics, 65
- orbitofrontal cortex
  - reward processing, 203
- orexigenic (appetite stimulating) neuropeptides, 36–37
- orexin, 412
  - role in sleep regulation, 138–139
- oxytocin, 34, 38, 39, 124, 167, 296, 412, 423
  - influence on attachment, 358
  - potential to generate an ethnocentric-like response, 167
- oxytomodulin, 124
- pain. *See* nociception and pain
- paliperidone, 155, 520
- pancuronium, 30
- panic disorders, 152
- Papez's circuit, 108
- Papez's loop, 86
- parasomnias, 518–519
- parasympathetic nervous system, 82
- parental postnatal depression
  - impact on child neurodevelopment, 370
- Parkinson's disease, 62, 65, 112, 113, 152, 178, 179, 469, 519
  - animal models, 68
  - apathy and anhedonia, 233, 234
  - decrease in grey matter volume, 345
  - See also* neurodegeneration.
- parkinsonism, 28, 472–473
  - drug induced, 182
- paroxetine, 211, 503
- patch clamp technique, 56
- Pavlov, Ivan, 200
- Pavlovian conditioning, 184
- peptide YY (PYY), 124
- perception, 219–223
  - auditory system, 220
  - beyond feature analysis, 220–221
  - feature analysis, 219–220
  - gnostic unit hypothesis, 222
  - identification of objects, 222
  - illusions and hallucinations, 222–223
  - influence of context and experience, 222–223
  - outstanding questions, 223
  - perceptual organisation, 220–222
  - visual system, 219–220
- perinatal disorders, 509–514
  - circadian rhythm disruption and, 512
  - classification, 509–510
  - features of, 509–510
  - future directions, 513
  - genetic factors, 512
  - heritability, 512
  - hormonal factors, 510–512
  - immunological factors, 512
  - impact of parental postnatal depression on child neurodevelopment, 370
  - inflammation and, 512
  - influence of sex hormones, 151
  - neuroimaging, 513
  - outstanding questions, 514
  - severe mood disorders triggered by childbirth, 509–510
  - triggering mechanisms, 510–512
- periodic limb movement disorder (PLMD), 519
- peripheral nervous system (PNS), 77
  - autonomic nervous system, 81
  - cranial nerves, 82–83
  - nerve plexuses, 82
  - neuroanatomy, 81–83
  - spinal nerves, 82
  - voluntary nervous system, 81
- persistent physical symptoms, 490
- pharmacological MRI (phMRI), 64
- pharmacology of neurotransmitter pathways, 27–31
- phasic neuronal activity, 110
- phencyclidine (PCP), 32, 42, 50
- phenelzine, 28
- β-phenethylamine, 19
- phenobarbital, 29
- phenylalanine, 19
- phenylketonuria, 383
- phenytoin, 32, 178
- physostigmine, 503
- pia mater, 84
- Pick's disease, 253
- pindolol, 166
- pineal gland, 107
- pituitary gland, 81, 112
  - functions of the posterior pituitary, 296
  - neuroanatomy, 287
  - posterior pituitary dysfunction in psychiatry, 296–297
  - regulation by the hypothalamus, 287
- plasticity in neuronal circuits, 10
- pleasure
  - imaging in humans, 204
  - role of the dopamine system, 204
  - See also* reward.
- polycystic ovary syndrome, 392
- polysomnography, 59
- pons, 81
- positron emission tomography (PET), 61–62
- posterior pituitary
  - dysfunction in psychiatry, 296–297
  - functions of, 296
  - syndrome of inappropriate ADH secretion (SIADH), 296–297
- post-mortem brain tissue analysis, 57

## Index

- postnatal depression. *See* perinatal disorders  
 post-partum depression, 154  
 postpartum psychosis. *See* perinatal disorders  
 post-traumatic stress disorder (PTSD), 50, 152, 155, 161, 358, 416–423  
   altered states of consciousness, 419–420  
   association with immune alterations, 318  
   behavioural sensitisation, 418  
   clinical features, 417  
   enhanced stress sensitivity, 418  
   epidemiology, 416–417  
   failure of fear extinction, 419  
   fear conditioning, 418–419  
   medication-assisted psychotherapies, 423  
   memory deficits, 249  
   need to identify risk and resilience markers, 416  
   neuroanatomical changes, 492  
   neurobiological and psychobiological mechanisms, 417–420  
   neuroscience-based treatment strategies, 421–423  
   outstanding questions, 423  
   pharmacotherapies, 422–423  
   predictors of, 416–417  
   prevalence of, 416  
   psychological trauma, 416  
   psychological treatments, 422  
   recognition of the condition, 416  
   risk factors, 416–417  
   role of cortisol dysregulation, 314  
   role of the HPA axis, 417  
   trauma-related dissociation, 419–420  
   treatments for, 249  
 poverty  
   impact on neurodevelopment, 368  
 Prader–Willi syndrome, 124, 382, 383  
 prazosin, 423  
 prediction error-driven learning, 184  
 predictive validity, 67  
 prednisolone, 303, 310  
 prefrontal cortex  
   involvement in various executive functions, 255–261  
 pregabalin, 32, 173, 520  
 pregnenolone, 154  
 premenstrual dysphoric disorder (PMDD), 151  
 pre-propeptides, 34  
 primary progressive aphasia (PPA), 275  
 prion disease, 559, 560  
 procyclidine, 181, 503  
 prodynorphin, 35  
 proenkephalin, 35  
 progressive supranuclear palsy, 557, 559, 560, 563, 565, 567  
 prolactin  
   hypothalamic–prolactin axis, 295–296  
 prolactinoma, 296  
 prolonged exposure (PE) therapy, 422  
 promethazine, 503  
 proopiomelanocortin (POMC), 35–36  
 propranolol, 166, 423  
   effectiveness in anxiety disorders, 211  
 pseudo-Cushings syndrome (non-tumoral hypercortisolism), 291  
 psilocybin  
   effects on neurotransmission, 50–51  
   overview of effects, 45  
 psychedelic drugs  
   effects on neurotransmission, 50–51  
   overview of effects, 45  
 psychoactive medication  
   Neuroscience Based Nomenclature (NbN3), 27  
 psychomotor retardation, 178  
 psychomotor therapy, 422  
 psychopathy, 162, 261  
 psychosis, 456–463  
   aberrant salience hypothesis, 460  
   altered inference (jumping to conclusions), 460  
   altered self-monitoring, 458  
   approach to understanding, 456  
   comparing psychosis models, 463  
   core features, 456–457  
   delusions, 456–457  
   effects of dopamine dysfunction, 28  
   explaining abnormal experiences and beliefs (two-factor theory), 460–461  
   hallucinations, 456–457  
   illusions, 457  
   linking to neurochemical underpinnings, 462–463  
   models of delusions, 459–460  
   models of hallucinations, 458  
   models of psychosis, 458  
   neuroscience of, 457–458  
   outstanding questions, 463  
   perception as inference, 461–462  
   perceptual changes, 456–457  
   predictive processing theories, 461–462  
   putamen, 90  
 quetiapine, 28, 155, 181, 503, 520  
 quinagolide, 296  
 raclopride, 204  
 radiculopathies, 179  
 raloxifene, 154  
 raphe nuclei, 111–112  
 reboxetine, 30  
 receptors, 10–11  
   acetylcholine receptors, 30  
   AMPA receptors, 31  
   classification of, 22–23  
   dopamine receptors, 28  
   drug targets, 24–25  
   G protein-coupled receptors (GPCRs), 34, 35, 38  
   GABA receptors, 29–30  
   glutamate receptors, 31  
   ionotropic receptors, 17, 22–23  
   kainate receptors, 31  
   long-term potentiation (LTP) process, 31  
   metabotropic receptors, 17, 22–23

- muscarinic receptors, 30
- nicotinic receptors, 30
- NMDA receptors, 31
- noradrenaline receptors, 30
- serotonin receptors, 28
- targeting neuropeptide receptors for therapy, 38
- types of neuronal receptors, 24–25
- recreational drugs
  - depressants, 45–49
  - movement disorders related to, 129
  - overview of effects, 45
  - psychedelic drugs, 50–51
  - stimulants, 49–51
  - See also specific drugs.*
- reinforcement learning, 185–187, 200–201
- REM behaviour disorder, 519
- repetitive transcranial magnetic stimulation (rTMS), 65, 493
- resilience to adversity
  - biological resilience factors, 371
  - neurodevelopmental factors, 370–371
  - social resilience factors, 370
- response inhibition
  - aspect of executive function, 255
- restless legs syndrome (Willis–Ekbom disease), 519
- reticular formation, 81
- Rett syndrome, 383
- reward
  - dopamine reward signal, 202
  - drug use and the meso-corticolimbic system, 403–404
  - factors influencing reward utility, 201
  - functions of reward, 199
  - hedonic food intake, 121
  - imaging of pleasure in humans, 204
  - measurement of reward signals in the brain, 201
  - neural circuits, 199–205
  - neuronal reward systems, 201–204
  - orbitofrontal cortex reward processing, 203
  - outstanding questions, 204
  - positive motivation and reward choice, 201
  - processing in the amygdala, 203–204
  - reinforcement learning, 200–201
  - related to aggression, 166
  - reward prediction, 200–201
  - role of dopamine, 112–113
  - role of leptin in food reward, 122–123
  - role of the dopamine system in pleasure, 204
  - striatal reward processing, 202
  - subjective reward value (economic utility), 199
- reward prediction error, 110, 113
- rimonabant, 125
- risperidone, 166, 181, 520
- Ritalin, 226, 229
- rivastigmine, 30, 249, 503
- Sacks, Oliver, 490
- schizophrenia, 19, 32, 110, 112, 113, 152, 154, 181, 467–473
  - affective symptoms, 473
  - anatomical abnormalities, 467–468
  - animal models, 68
  - apathy and anhedonia, 233, 234
  - application of learning models, 187–189
  - association with immune alterations, 318
  - attentional deficits, 229–230
  - brain network abnormalities, 280
  - catatonia, 473
  - cognitive symptoms, 472
  - comorbidity, 473
  - dopamine neurotransmission, 469–471
  - dyskinesias, 472–473
  - electrophysiological studies, 468–469
  - features of, 467
  - functional connectivity abnormalities, 469
  - genetic factors, 469
  - GWAS and post-GWAS analysis, 330–331
  - heritability, 327, 469
  - hypofrontality, 253
  - immunology, 471
  - information filtering and processing abnormalities, 468–469
  - liking (subjective enjoyment), 235
  - motor symptoms, 472–473
  - negative symptoms (deficit syndrome), 472
  - neurochemistry, 469–471
  - neuroscience of specific symptoms, 471–473
  - neurotransmitter genes implicated by GWAS, 41–42
  - outstanding questions, 473
  - parkinsonism, 472–473
  - patterns of atypical development, 350
  - psychotic symptoms, 471–472
  - rate of rare copy number variants, 333
  - role of neurotransmitters, 469–471
  - sleep disorders, 520
  - working memory deficits, 257
- schizophrenia spectrum disorders
  - Theory of Mind deficits, 267–268
- Schwann cells, 10, 13
- scopolamine, 113, 503
- seizures. *See* epilepsy and seizures
- selective androgen receptor modulators (SARMs), 154–155
- selective oestrogen receptor modulators (SERMs), 154–155
- selective serotonin reuptake inhibitors (SSRIs), 27, 155, 167, 211, 313
  - effects on appetite and weight, 124–125
  - use in anxiety disorders, 411
- self-harm, 484–488
  - approach to the evidence, 484
  - brain imaging, 485–486
  - features of, 484
  - genetic factors, 487
  - limitations of the literature, 487
  - neurochemistry of, 487
  - neuropsychology of, 486
  - outstanding questions, 488
- seltorexant, 38
- Selye, Hans, 300
- semantic dementia, 275
- sensitive periods in neurodevelopment, 368

**Index**

- serotonin, 18, 20  
 ascending neurotransmitter system, 111–112  
 basic pharmacology, 27–28  
 effects on sleep and arousal, 135  
 key cognitive functions, 115  
 role in violence and aggression, 165–166
- serotonin and noradrenaline reuptake inhibitors (SNRIs), 27, 30, 156
- serotonin antagonist and reuptake inhibitors (SARIs), 155
- serotonin receptors, 28
- serotonin reuptake inhibitors, 182
- serotonin transporter (SERT), 20, 27
- sex and sex hormones, 146–157  
 brain sex differences related to hormones and genes, 146–147  
 gender affirming hormonal therapy (GAHT), 157  
 gender identity, 157  
 hormonal treatments for psychiatric disorders, 154–155  
 influence on psychiatric disorder susceptibility, 149–154  
 origins of brain sex differences, 146–147  
 outstanding questions, 157  
 role of sex hormones in neurodevelopment, 367  
 role of sex hormones in pathophysiology, 149–153  
 sex and gender, 147  
 sex bias in psychiatric disorders, 149–154  
 sex differences in brain disorders, 146–147  
 sex differences in midbrain dopaminergic systems, 148–149  
 sex-specific effects of early life challenges, 153–154  
 sexual dysfunction related to psychiatric disorders, 155  
 sexual dysfunction related to psychoactive medications, 155
- sexsomnia, 518
- sexually-dimorphic brain circuits, 367
- signal transduction systems  
 role in bipolar affective disorder, 450
- Simon, Théodore, 378
- single nucleotide polymorphisms (SNPs), 41
- single-photon emission computed tomography (SPECT), 62
- sleep, 129–143  
 arousal and wake-promoting systems, 132–139  
 ascending cholinergic and monoaminergic systems, 134–138  
 assessment of, 129–143  
 circadian rhythm, 140–141  
 effects of sleep deprivation, 142  
 GABAergic and glutamatergic arousal system, 133–134  
 involvement of neuropeptides, 37–38  
 neural circuits involved in sleep regulation, 132–140  
 non-rapid eye movement (NREM) sleep, 129  
 outstanding questions, 143  
 polysomnography, 129  
 rapid eye movement (REM) sleep, 129  
 REM sleep regulation, 140  
 role of the hypocretin (orexin) system, 138–139  
 sleep-promoting mechanisms, 139–140  
 stages of, 129  
 two-process model of sleep regulation, 130–132
- sleep disorders, 517–520  
 central disorders of hypersomnolence, 518  
 circadian rhythm sleep–wake disorders, 518  
 effects of impaired orexin signalling, 37–38  
 effects of medications on sleep, 520  
 insomnia, 517–518  
 movement disorders, 519  
 narcolepsy, 37–38, 518  
 obstructive sleep apnoea (OSA), 518  
 outstanding questions, 520  
 parasomnias, 518–519  
 periodic limb movement disorder (PLMD), 519  
 primary sleep disorders, 517–519  
 REM behaviour disorder, 519  
 restless legs syndrome (Willis–Ekbom disease), 519–520  
 role in psychiatric disorders, 519–520  
 sleep-related breathing disorders, 518
- sleep-related eating disorder, 518
- sleep terrors, 518
- sleepwalking, 518, 519
- social and ‘hot’ cognition  
 role of the prefrontal cortex, 260–261
- social functioning  
 role of neuropeptides, 38
- social intelligence  
 evolution of Theory of Mind, 263–264
- sociopathy, 162
- sodium oxybate, 520
- sodium pump membrane transporter, 7
- sodium valproate, 125, 182
- somatic symptom disorder (DSM-5), 490
- somatoform disorder, 490–491
- somatoform disorders (ICD-10), 490
- Spearman, Charles, 378
- spice (synthetic marijuana), 181
- spinal cord  
 neuroanatomy, 81
- spinal nerves, 82
- Stanford–Binet Test, 378
- statistical modelling, 69–70
- Stern, William, 378
- stimulant recreational drugs, 49–51
- Strange Stories Test, 268
- Strattera, 229
- stress  
 impact on neurodevelopment, 368–371  
 interventions to rescue stress-induced neuroplasticity, 371–372  
 role in immune dysregulation, 321  
 Trier Social Stress Test (TSST), 321
- stress-related disorders  
 genome-wide association study (GWAS), 330  
 sex differences, 152
- stress responses, 300–304  
 actions of glucocorticoids on the brain, 302–303  
 consequences of raised corticoids, 303–304  
 cortisol release, 301–302

- effects of raised corticoids on glia, 303
- effects of raised corticoids on neurons, 303
- effects on mood and cognition in humans, 303–304
- elevated secretion of glucocorticoids, 301–302
- endocrine responses, 301–302
- HPA axis response, 301–302
- nature of stress, 300–301
- outstanding questions, 304
- role of serotonin, 112
- role of the glucocorticoid receptor (GR), 302–303
- stages of stress (Selye), 300
- types of stressor, 300
- striatum
  - reward processing, 202
- stroke, 31, 61, 179, 233
  - post-stroke language impairments, 273–275
- Stroop task, 259
- structural equation modelling (SEM), 69
- structural MRI, 62–64
- subarachnoid space, 84
- substantia nigra, 90, 112
- subthalamic nucleus, 90
- suicidality, 484–488
  - approach to the evidence, 484
  - brain imaging, 485–486
  - features of, 484
  - genetic factors, 487
  - limitations of the literature, 487
  - neurochemistry of, 487
  - neuropsychology of, 486
  - outstanding questions, 488
  - risk following epilepsy diagnosis, 540
- sulpiride, 178
- suprachiasmatic nucleus (SCN), 80, 130, 289
  - inputs to, 140
  - molecular regulation of the circadian clock, 140–141
  - outputs from, 140
  - role as circadian pacemaker, 140
- sympathetic nervous system, 82
  - synapses, 10
  - See also* chemical synapses.
- syndrome of inappropriate ADH secretion (SIADH), 296–297
- tamoxifen, 155
- tardive dyskinesia, 182
- temporal lobes, 97–100
- Terman, Lewis, 378
- tetrabenazine, 178
- thalamus, 80, 102, 113
- Theory of Mind, 260, 263–268
  - definition of, 263
  - development in human children, 265
  - evolution of social intelligence, 263–264
  - in patients with autism spectrum disorder (ASD), 265
  - in patients with schizophrenia spectrum disorders, 267–268
- informational ToM, 265
- levels of complexity, 264–265
- motivational ToM, 264–265
- outstanding questions, 268
- perceptual ToM, 264
- research challenges, 264
- Sally-Anne experiment, 265
- testing impairments in mentalisation, 268
- thirst
  - relationship to appetite, 125
- Thompson, Godfrey, 378
- thyroid hormone therapy
  - use in unipolar and bipolar depression, 292–293
- thyrotoxicosis, 291–292
- tobacco, 37
- tonic neuronal activity, 110
- Tourette syndrome, 92, 180
- trace amine associated receptors (TAARs), 19
- trace amines, 19
- transcranial direct current stimulation (tDCS), 65, 549–550
- transcranial magnetic stimulation (TMS), 187, 549–550
- transcriptomics
  - insights into neurodevelopment, 351
- tranylcypromine, 28
- traumatic brain injury, 233
- trazodone, 30, 520
- trichotillomania
  - definition of, 429
  - See also* obsessive–compulsive and related disorders (OCRDs).
- tricyclic antidepressants (TCAs), 27, 30, 156, 173, 182, 503
- Trier Social Stress Test (TSST), 321
- trimipramine, 520
- tryptophan, 20
- tuberoinfundibular dopaminergic (TIDA) system, 155
- Turner's syndrome, 383
- Type I error, 69
- Type II error, 69
- Tyrer, Peter, 211
- tyrosine, 19
- unexpected uncertainty, 113–114
  - role in psychiatric disorders, 111
- Urbach–Wiethe disease, 214
- vagus nerve, 83, 124
- vagus nerve stimulation (VNS), 66, 83
- valproate, 42
- valproic acid, 503
- vascular dementia, 233
- vasopressin, 125
- velo-cardio-facial syndrome, 383, 541
- venlafaxine, 27, 124, 156, 523
- ventral striatum, 90
- ventral tegmental area, 112
- vesicular monoamine transporter (VMAT), 20

## Index

- vesicular transporter for glutamate (vGluT), 32
- vigilance, 225
- violence and aggression, 161–168
  - animal models, 162
  - cortical control, 163
  - definition of aggression, 161
  - definition of violence, 161
  - maladaptive behaviour, 161–162
  - midbrain and brainstem control, 163–164
  - neural networks involved, 162–164
  - neurotransmitters and modulators, 164–167
  - outstanding questions, 168
  - premeditated (proactive) aggression, 162
  - reactive aggression, 161–162
  - reward related to aggression, 166
  - role of dopamine, 166
  - role of noradrenaline, 166–167
  - role of serotonin, 165–166
  - translational models of maladaptive aggression, 162
  - treatment strategies based on neuroscience, 167
  - types of aggression, 161–162
  - understanding the neuroscience of, 161
- virtual reality exposure therapy (VRET), 422
- visceral sensory nervous system, 82
- visual system, 219–220
- Vogt, Oskar, 85
- Vogt-Mugnier, Cecile, 85
- voluntary nervous system, 81
- vortioxetine, 155
- waxy flexibility, 181
- Wechsler Adult Intelligence Scale (WAIS), 379
- Wernicke's aphasia, 273–274, 275
- white matter, 10, 77, 84, 85
  - maturation of, 345–346
- white matter pathways, 105–108
  - association fibres, 105–106
  - commissural fibres, 106–107
  - limbic system, 108
  - Papez's circuit, 108
  - projection fibres, 107–108
- William's syndrome, 383
- Willis–Ekbom disease (restless legs syndrome), 519
- Wilson's disease, 179
- yoga, 422
- ziprasidone, 155
- zolpidem, 520
- zopiclon, 524